Back to Tirzepatide research
tirzepatide gip agonist rct 2019-06-03 ClinicalTrials

Tirzepatide Shows Significant Efficacy for Type 2 Diabetes in Phase 3 Trial

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Background

Type 2 Diabetes Mellitus is a chronic metabolic condition characterized by high blood sugar, often managed initially with diet and exercise. However, many patients struggle to achieve adequate glycemic control through lifestyle changes alone, necessitating pharmaceutical interventions. This Phase 3 trial aimed to evaluate the efficacy and safety of tirzepatide in patients whose Type 2 Diabetes is not controlled by lifestyle interventions alone, providing a potential new treatment option.

Study Design

Population
Patients with Type 2 Diabetes Mellitus whose condition is not controlled by lifestyle interventions alone.
Intervention
Tirzepatide at multiple effective doses.
Outcome
Efficacy and safety of tirzepatide in achieving glycemic control.

tirzepatide gip agonist glp 1 agonist dose mentioned protocol relevant
Source: clinicaltrials:NCT03954834 · Ingested 2026-04-24 · Digest: gemini-2.5-flash